Assessing anaphylactic risk? Consider mast cell clonality
- PMID: 19281912
- PMCID: PMC2782434
- DOI: 10.1016/j.jaci.2009.02.003
Assessing anaphylactic risk? Consider mast cell clonality
Comment on
-
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.J Allergy Clin Immunol. 2009 Mar;123(3):680-6. doi: 10.1016/j.jaci.2008.11.018. Epub 2009 Jan 9. J Allergy Clin Immunol. 2009. PMID: 19135713
References
-
- Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fiore D, et al. Clonal mast cells disorders in patients with systemic reactions to hymenoptera sting and raised serum tryptase. J Allergy Clin Immunol. In press. - PubMed
-
- Schwartz LB, Bradford TR, Rouse C, Irani A-M, Rasp G, Van der Zwan JK, et al. Development of a new, more sensitive immunoassay for human tryptase: Use in systemic anaphylaxis. J Clin Immunol. 1994;14:190–204. - PubMed
-
- Ludolph-Hauser D, Rueff F, Fries C, Schopf P, Przybilla B. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet. 2001;357(9253):361–2. - PubMed
-
- Simons FE, Frew AJ, Ansotegui IJ, Bochner BS, Golden DB, Finkelman FD, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol. 2007;120(1 Suppl):S2–24. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
